Research in the Robert Gilman Lab focuses on disease control. Our work led to the development of microscopic-observation drug-susceptibility (MODS), a rapid tuberculosis diagnostic technique. We continue to conduct infectious disease research based at Peru’s Universidad Peruana Cayetano Heredia.

Research in the Redonda Miller Lab is focused on women’s health, including osteoporosis and menopause, and medical education. We're also interested in physician practice issues.

Research in the Amy Knight Lab focuses on methods by which information technology can improve the quality of health care. We investigate the role computer systems can play in expanding patient-doctor communication, streamlining healthcare tasks for both medical students and practitioners, and establishing a higher standard of care. Our studies have explored the effectiveness of semi-automating daily progress notes for improved documentation, peer assessment of professional performance among hospitalists, ways to enable patient-centered care using information technology and other topics.

The Anna Durbin Lab evaluates experimental vaccines through human clinical trials. We have conducted both pediatric and adult clinical trials on vaccines for HIV, hepatitis C, HPV, influenza, malaria, dengue virus, rotavirus and other viruses. We also have a longstanding interest in better understanding the immunologic factors of dengue infection and disease. We’re working to identify the viral, host and immunologic factors that cause severe dengue illness.

The Amita Gupta Lab focuses on drug trials to prevent and treat HIV, tuberculosis (TB) and other co-morbidities in adults, including pregnant women and children who reside in low-income settings. We also conduct cohort studies assessing HIV, inflammation and nutrition in international settings; TB in pregnancy; and risk factors for TB in India (CTRIUMPH). We collaborate with several faculty in the Center for TB Research, Division of Infectious Diseases and the School of Public Health.

Research in the Alan Baer Lab focuses on Sjogren's syndrome. Previously, we conducted the Sjogren's International Registry (SICCA), enrolling 300 patients and creating a valuable source of clinical data and biospecimens for research we're conducting with colleagues at Johns Hopkins and the University of California-San Francisco. Currently, we're conducting a longitudinal observational study of patients with Sjogren's syndrome. We're also collaborating with Dr. Ben Larman in the Department of Pathology, using phage immuno-precipation sequencing to work on a characterization of the complete autoantibody repertoire in Sjogren's syndrome patients.

The Alain Labrique Lab conducts research on infectious diseases and public health. Our team studies the various factors that lead to maternal and neonatal mortality, particularly in underserved populations in South Asia, using the tools of infectious disease epidemiology, molecular biology and biostatistics. We work to better understand factors such as the interface of micronutrient deficiency and maternal/infant mortality and the prevention of nosocomial infections through mechanistic or nutritional interventions. We also have a longstanding interest in technologies that may enable early detection of disease.

Dr. Meltzer is an internationally renowned leader in the molecular pathobiology of gastrointestinal malignancy and premalignancy. He invented molecular methods to detect loss of heterozygosity in tiny biopsies, triggering an avalanche of research on precancerous lesions. He was the first to comprehensively study coding region microsatellite instability, leading to the identification of several important tumor suppressor genes. He performed several groundbreaking genomic, epigenomic and bioinformatic studies of esophageal and colonic neoplasms, shifting the GI research paradigm toward genome-wide approaches. He directed an ambitious nationwide validation study of DNA methylation-based biomarkers for the prediction of neoplastic progression in Barrett’s esophagus. Dr. Meltzer founded and led the Aerodigestive Cancer and Biomarker Interdisciplinary Programs at the University of Maryland, also becoming associate director for core sciences at that school’s Cancer Center. He currently holds an endowed professorship and is the director of GI biomarker research at Johns Hopkins. The laboratory group focuses its efforts on the molecular genetics of gastrointestinal cancers and premalignant lesions, as well as on translational research to improve early detection, prognostic evaluation, and treatment of these conditions. Below, some examples of this work are described.

The research mission of the Zackary Berger Lab is to bridge evidence-based medicine and shared decision-making in the context of patient-centered care. Lab studies investigate how to accomplish this in the common case of uncertainty, while seeking to clarify the ethics of decision-making and empirically describe how shared decision-making is and should be done. Zackary Berger, MD, PhD, is an assistant professor in the Division of General Internal Medicine at the Johns Hopkins School of Medicine. In addition to his work as an internist and primary care physician, Dr. Berger is an associate faculty member in the Berman Institute of Bioethics, and core faculty in the Evidence Based Practice Center as well as the Center for Health Services and Outcomes Research.

Research in the Zishan Siddiqui Lab focuses on patient-centered care and satisfaction, preoperative medicine and clinical reasoning. We are also interested in international medicine. In a previous collaboration with Daniel Brotman, M.D., we discovered that hospital renovations do not improve patient satisfaction.